Marksans Pharma Share Price

NSE
MARKSANS •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Marksans Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
137.81% Gain from 52W Low
40.2
TTM PE Ratio
Below industry Median
40.4
Price to Book Ratio
Above industry Median
6.7
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is much higher than 1
2.4

Marksans Pharma Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Marksans Pharma Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
641.92 Cr
590.62 Cr
560.01 Cr
586.13 Cr
531.24 Cr

Marksans Pharma Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
2227.83 Cr
1911.45 Cr
1532.69 Cr
1382.88 Cr
1134.54 Cr

Marksans Pharma Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
97.76 Cr
89.07 Cr
77.64 Cr
82.96 Cr
83.85 Cr

Marksans Pharma Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
314.9 Cr
265.32 Cr
186.81 Cr
238.54 Cr
120.75 Cr

Marksans Pharma Ltd shareholding Pattern

Promoter
43.9%
Foreign Institutions
21.3%
Mutual Funds
3%
Domestic Institutions
4.1%
Public
30.7%
Promoter
43.9%
Foreign Institutions
18.6%
Mutual Funds
2.8%
Domestic Institutions
3.8%
Public
33.8%
Promoter
43.8%
Foreign Institutions
15.6%
Mutual Funds
4.2%
Domestic Institutions
5.2%
Public
35.4%
Promoter
43.8%
Foreign Institutions
15.6%
Mutual Funds
3.8%
Domestic Institutions
4.8%
Public
35.8%
Promoter
43.8%
Foreign Institutions
15.1%
Mutual Funds
3.2%
Domestic Institutions
4%
Public
37.1%
Promoter
43.8%
Foreign Institutions
14.9%
Mutual Funds
2.8%
Domestic Institutions
3.6%
Public
37.6%

Marksans Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
306.20
10Day EMA
302.00
12Day EMA
300.50
20Day EMA
295.90
26Day EMA
293.30
50Day EMA
281.30
100Day EMA
254.80
200Day EMA
217.60
5Day SMA
307.60
10Day SMA
302.40
20Day SMA
290.70
30Day SMA
289.40
50Day SMA
290.30
100Day SMA
248.40
150Day SMA
219.60
200Day SMA
203.00
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
783891 Rs
2138992 Rs
Week Rs
767662 Rs
2231782 Rs
Month Rs
658420 Rs
2459845 Rs
Resistance & Support
305.42
Pivot
Resistance
First Resistance
313.73
Second Resistance
318.32
Third Resistance
326.63
Support
First Support
300.83
Second support
292.52
Third Support
287.93
Relative Strength Index
61.12
Money Flow Index
75.46
MACD
7.21
MACD Signal
5.44
Average True Range
14.27
Average Directional Index
21.10
Rate of Change (21)
12.81
Rate of Change (125)
85.40

Marksans Pharma Ltd Company background

Founded in: 1992
Managing director: Mark Saldanha
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Companys research and development facilities are located in Verna, Goa and R D center in Navi Mumbai.In 200405, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005 further, it acquired two companies, Bell Sons Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired TimeCap Laboratories Inc. in the US in 2015. The Company launched the CNSCerebella division in FY 201718. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new RD center at Navi Mumbai, apart from one in Goa in 201920. The Company acquired the business of Tevapharm India Private Limited relating to the manufacture and supply of pharmaceutical formulations in Verna, Goa as a going concern on a slump sale in April, 2023.
Read More

Marksans Pharma Ltd FAQs

Marksans Pharma Ltd shares are currently priced at 309.15 on NSE and 309 on BSE as of 11/19/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Marksans Pharma Ltd [MARKSANS] share was 122.41. The Marksans Pharma Ltd [MARKSANS] share hit a 1-year low of Rs. 130 and a 1-year high of Rs. 328.8.

The market cap of Marksans Pharma Ltd is Rs. 14009.56 Cr. as of 11/19/2024 12:00:00 AM.

The PE ratios of Marksans Pharma Ltd is 91.15 as of 11/19/2024 12:00:00 AM.

The PB ratios of Marksans Pharma Ltd is 10.84 as of 11/19/2024 12:00:00 AM

The Mutual Fund Shareholding was 3.02% at the end of 11/19/2024 12:00:00 AM.

You can easily buy Marksans Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -